Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart in Moderately to Severely Active Ulcerative Colitis
NCT06589986Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2024
- Primary completion
- Jan 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 30
01
Overview
A Phase 3 trial of afimkibart in ulcerative colitis (UC), sponsored by Roche. Started Sep 2024; status: active, not recruiting.
02
Drugs
afimkibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06589986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589986.